Private Equity Firm Healthcare

Casdin Capital

New York, New York, United States

Casdin Capital is a New York research investment firm focused on innovations in molecular medicine reshaping life sciences and healthcare. It partners with industry leaders as an investor-partner in both private and public companies, targeting long-term returns from disruptive technologies.

Focus Areas
Life Sciences, Molecular Medicine

Tracked deals

3

3 tracked deals across 2023-2026.

Recent pace

1

1 tracked deal announced in the last 12 months.

Deal mix

Growth capital

2 growth capital · 1 buyout

Casdin Capital Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for Casdin Capital. 1 2023 1 2024 ~1 est. 1 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Investor Group Provides $120 Million Private Placement to Bolt Biotherapeutics
    October 24, 2026
    Buyer
    Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Coastlands Capital, Eventide Asset Management, Casdin Capital, Curie.Bio, SilverArc Capital, Soleus Capital, Deviation Capital, YK Bioventures
    Target
    Bolt Biotherapeutics
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Growth capital

    Bolt Biotherapeutics secured a concurrent $120 million private placement from Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Coastlands Capital, Eventide Asset Management, Casdin Capital, Curie.Bio, SilverArc Capital, Soleus Capital, Deviation Capital, and YK Bioventures. The financing is intended to fund Bolt’s operations into 2028 and advance PRA-216 and other pipeline programs; warrants could provide an additional $60 million.

  • Century Therapeutics Acquires Clade Therapeutics; Raises $60M Private Placement Led by Bain Capital Life Sciences
    April 11, 2024
    Buyer
    Century Therapeutics, Bain Capital Life Sciences, Adage Capital Partners LP, Octagon Capital, Superstring Capital, Casdin Capital, Boxer Capital, Venrock Healthcare Capital Partners, DAFNA Capital Management, LLC
    Target
    Clade Therapeutics
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Century Therapeutics agreed to acquire privately held Clade Therapeutics for approximately $35 million in upfront consideration (plus a potential $10 million milestone) to expand its iPSC-derived cell therapy pipeline and next-generation Allo-EvasionTM platform. Concurrently, Century completed a roughly $60 million private placement led by Bain Capital Life Sciences and several institutional investors to support expanded autoimmune development of its lead program CNTY-101 and extend cash runway into 2026.

  • a16z and Section 32 Lead $28M Series A in Function Oncology
    April 17, 2023
    Buyer
    Andreessen Horowitz, Section 32, Casdin Capital, Alexandria Venture Investments
    Target
    Function Oncology
    Industry
    Biotechnology
    Location
    United States
    Type
    Growth capital

    Function Oncology, a precision medicine company developing a CRISPR-powered functional genomics platform for personalized cancer profiling, closed a $28 million Series A led by Andreessen Horowitz and Section 32 with participation from Casdin Capital and Alexandria Venture Investments. The funding will support development and scaling of Function Oncology's platform to identify patient-specific drug target dependencies and accelerate diagnostic and therapeutic applications.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 3 tracked deals by Casdin Capital. Acquisitions in California 1 tracked deal by Casdin Capital. Acquisitions in Massachusetts 1 tracked deal by Casdin Capital.

Related articles

Selling a company? Get in front of buyers like Casdin Capital

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →